IHS FormWeb
Approved Formulary
Search by name
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Search results for:
edoxaban
edoxaban
Restricted Medications
Non-Formulary / Not-stocked
Brand names:
Savaysa
No brands, forms, or strengths have been added for this generic.
Display
Direct Factor Xa Inhibitors
Class:
20120414
Medication comments:
2023 American Geriatrics Society Beers Criteria
®
for potentially inappropriate medication use in older adults.
View all
Reference
Medication:
edoxaban (Savaysa)
Criteria 5: medications that should be avoided or have their dosage reduced with varying levels of
kidney function
in older adults. (Table 6)
CrCl (mL/min) at which action is required
15-50
<15 or > 95
Rationale
Lack of evidence of efficacy or safety in patients with CrCl <30 mL/min.
Recommendation
Reduce dose if CrCl is 15-50 mL/min.
Avoid if CrCl <15 or > 95 mL/min.
Quality of evidence:
Moderate
, Strength of Recommendation:
Strong
Last updated:
Sep. 20, 2025
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online
UpToDate Lexidrug
<15 or > 95
Avoid if CrCl <15 or > 95 mL/min.